ESC 2023 | ECLS-Shock

Cardiogenic shock (CS) represents the main cause of death in patients hospitalized for acute myocardial infarction (AMI). Despite advances in its management, mortality continues to be high, between 40-50% within the first 30 days. In an attempt to improve survival, early extracorporeal life support (ECLS) is being increasingly used to stabilized hemodynamics in cases of serious shock, especially the use of venoarterial extracorporeal membrane oxygenation (VA-ECMO), also called ECLS. 

ESC 2023

Evidence on the efficacy of VA-ECMO in the context of AMI and CS is based mainly on observational studies or small randomized trials. The ECLS-SHOCK is the first randomized clinical trial on VA-ECMO to look into mortality in patients with CS undergoing early revascularization. The study included patients from centers in Germany and Slovenia, mean age 63, and 19% were women.

Primary end point was all-cause mortality at 30 days. Secondary end points included length of mechanical ventilation, time to hemodynamic stabilization and need for renal replacement therapy. As regards safety, researchers looked into bleeding events (from moderate to severe) and peripheral vascular complications requiring intervention. 

Read also: ESC 2023 | STOPDAPT-3.

The final analysis considered a total of 417 patients. Primary end point occurred in 47.8% patients in the VA-ECMO group and 49% in the control group ([RR] 0.98, CI 95%, 0.80-1.19; p=0.81). Length of mechanical ventilation was higher in the VA-ECMO group (7 vs 5 days). Also, time to hemodynamic stabilization and need for renal replacement therapy rate were similar.  

As regards safety end points, there were more bleeding events in the VA-ECMO group (RR 2.44, CI 95% 1.50-3.95) and more interventions for peripheral vascular complications (RR 2.86, CI 95% 1.31-6.25).

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Source: Presented at the Hot Line Sessions, Agosto 26, ESC Congreess 2023, Amsterdam.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...

TCT 2024 – ECLIPSE: Randomized Study of Orbital Atherectomy vs Conventional PCI in Severely Calcified Lesions

Coronary calcification is associated with stent under-expansion and increased risk of both early and late adverse events. Atherectomy is an essential tool for uncrossable...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....